About Pharos iBio

The Best Target & The Best Chemical

  • Start-up Challenge
  • Foundation Builder
  • Growth Leap Forward
History
Start-up Challenge 2016
  • 2016.04

    Foundation of Pharos I&BT Co., LTD.

  • 2016.06

    Certification of Venture Business

  • 2016.07

    Participation of join research (AML) on R&D support project of the New Drug Development Support Cent @ Ministry of Science and ICT → Derivation of newdrug candidate based on cardiac toxicity prediction using the Chemiverse platform

  • 2016.08

    Certification of R&D center(Bio & A.I.)

  • 2016.12

    Acute Myeloid Lekemia(AML) therapeutics technology transfer contract(exclusive development) signed

Foundation Builder 2017-2019
  • 2017.07

    Attraction of TIPS investment (₩100 million) from Chungbuk Bio Center for Creative Economy and Innovation

  • 2017.08

    PHI-101 Start of preclinical Tox study

    TIPS R&D, Start-up project (Total ₩580 million)

    4th Health and Medical Technology Research and Development project (₩1.05 billion)

  • 2017.11

    Qubest Bio (CharlesRiver Lab) Non-clinical toxicity test agreement

    Attration of individual angel investment funds (₩1.5 billion)

  • 2018.07

    JHU prof. Donald Small in US, Advisory contrat & joint research

  • 2018.08

    Successful attraction of series A investment(₩7.5billion) -> Korea investment partners, MiraeAsset Venture Investment, IMM investment, DSC investment

  • 2018.11

    Calvary Mater Hospital, Royal Prince Alfred Hospital in Australia, Consultation of phase I clinical trials

  • 2019.02

    Signed agreement on business with Korea Chemical Bank in KRICT (Project of building web-base integrated chemical DB for drug materials)

  • 2019.03

    Granted of PHI-101 AML patent registration in Korea (Patent No.10-1965326)

  • 2019.04

    PHI-101 received US Orphan Drug Designation for treatment AML

  • 2019.08

    Certification of INNOBIZ

    Establishment of the local subsidiary in Australia

  • 2019.12

    TGA in Australia has granted PHI-101 Phase 1 clinical trials

Growth Leap Forward 2020-
  • 2020.01

    Contract with Korea Investment & Securities for underwriter

  • 2020.02

    Approval From Korea MFDS on the IND of Phase 1 clinical trial of PHI-101

  • 2020.03

    Successful attraction of series B investment(₩16 billion) -> Korea investment partners, MiraeAsset Venture Investment, DSC investment, Company K Partners, Korea Investment & Securities

    Join Ph.D Han, senior researcher of Roche, as CDO

  • 2020.04

    Joint Research and Technology agreement with Yonsei University Health System (Joint Development of New Drugs for Target Anti-cancer Drugs)

    Establishment of the local subsidiary in USA (California, Silicon Valley)

  • 2020.08

    Pharos iBio, changed its name from Pharos I&BT

  • 2020.11

    Approval From Korea MFDS on the IND of Phase 1 clinical trial of PHI-101-002

  • 2020.12

    Contract with the designated auditor for listing

    Joint Research and Development agreement with Chungnam National Univ. (Development of new drug platform technology for discovering protein kinase inhibitors.)

  • 2021.01

    Joint Research and Development agreement with NGENbio (Co-Development of Companion Diagnostics of Next Generation FLT3 inhibitor, PHI-101)

    Participating in the 39th J.P. Morgan Healthcare Conference.

  • 2021.04

    Presentation about preclinical study of Ovarian and Breast cancer at the American Association for Cancer Research (AACR) 2021

    Excellent award winner of Health and Medical treatment R&D 2020 (Korea MOHW, KHIDI)

  • 2021.06

    Pharos iBio Co., Ltd. has secured a ₩18 billion Series C round. → UTC investment, Company K Partners, Solidus investment, Intops investment, LSK investment, KDB Capital, Timefolio Asset Management

  • 2021.08

    Additional establishment of the Seoul R&D Center(A.I. & Bio)

  • 2021.11

    Building a synthetic laboratory and bio laboratory at the headquarters.

    Designated as a Promising Start-up Company(Blue100) in 2021 by Anyan Business Agency

    PHI-501 received US Orphan Drug Designation for treatment AML

  • 2021.12

    Presentation of early clinical results of PHI-101 AML at the annual conference of the American Society of Hematologi, ASH

  • 2022.01

    Participating in the 40th J.P. Morgan Healthcare Conference.

  • 2022.02

    Participating in the UNIST Leukemia High-Precision Bio Research Group

  • 2022.03

    Preclinical results of PHI-501 presented by the American Cancer Society

    MOU on the development of innovative new drugs using Geninus and artificial intelligence closing

  • 2022.04

    Transfer and joint transfer of new KRAS Inhibitor technology with Yuhan Corporation conclusion of development agreement

  • 2022.05

    Technical evaluation passed (listed on KOSDAQ technical exception)

  • 2022.08

    Request for listing preliminary examination (listed on KOSDAQ technical exception)